Alvotech 과거 순이익 실적

과거 기준 점검 2/6

Alvotech은 연평균 7.8%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 28.3%의 비율로 증가했습니다. 매출은 연평균 56.6%의 비율로 증가했습니다.

핵심 정보

7.79%

순이익 성장률

15.82%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	56.64%
자기자본이익률	n/a
순이익률	4.74%
다음 순이익 업데이트	06 May 2026

최근 과거 실적 업데이트

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Nov 20

Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations

May 15

Recent updates

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Apr 10

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Nov 20

Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues

Nov 09

Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers

Nov 06

Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%

May 25

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

매출 및 비용 세부 내역

Alvotech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGM:ALVO 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
31 Dec 25	589	28	86	184
30 Sep 25	573	69	86	191
30 Jun 25	562	63	81	167
31 Mar 25	588	97	68	160
31 Dec 24	492	-232	65	171
30 Sep 24	394	-441	62	189
30 Jun 24	309	-618	-19	227
31 Mar 24	114	-494	67	191
31 Dec 23	93	-552	-8	211
30 Sep 23	64	-596	120	179
30 Jun 23	65	-416	82	175
31 Mar 23	100	-713	101	182
31 Dec 22	85	-514	163	181
30 Sep 22	96	61	51	171
30 Jun 22	78	-12	34	187
31 Mar 22	39	-42	66	190
31 Dec 21	40	-102	68	191
31 Dec 20	69	-170	59	146
31 Dec 19	83	-210	49	96

양질의 수익: ALVO의 비현금 수익 수준이 높습니다.

이익 마진 증가: ALVO는 과거에 흑자전환했습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: ALVO는 지난 5년 동안 흑자전환하며 연평균 7.8%의 수익 성장을 기록했습니다.

성장 가속화: ALVO는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.

수익 대 산업: ALVO는 지난해 흑자전환하여 지난 해 수익 성장률을 Biotechs 업계(50.1%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: ALVO의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/14 21:24
종가	2026/04/14 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Alvotech는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Glen Santangelo	Barclays
Andrew Baum	Citigroup Inc
Peter Verdult	Citigroup Inc

Alvotech 과거 순이익 실적

과거 기준 점검 2/6

핵심 정보

최근 과거 실적 업데이트

Alvotech to Report Q3, 2026 Results on Nov 11, 2026

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations

Alvotech to Report Fiscal Year 2024 Results on Mar 26, 2025

Alvotech to Report Q2, 2025 Results on Aug 14, 2025

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Recent updates

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Alvotech Reaffirms Earnings Guidance for 2026

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio

Lisa Graver to Step Down from the Board of Alvotech

Alvotech announced that it has received $100 million in funding

Alvotech, Annual General Meeting, Jun 03, 2026

Alvotech to Report Q3, 2026 Results on Nov 11, 2026

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Alvotech Reaffirms Earnings Guidance for 2025 and Provides Earnings Guidance for 2026

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Alvotech Revises Earnings Guidance for the Full Year 2025

Alvotech Announces the Outcome of Expedited Infringement Paving Way for Manufacture and Market Entry of AVT06, Biosimilar to Eylea®?

Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®?, a Biosimilar to Simponi®? (golimumab), from the MHRA

Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Advanz Pharma Holdco Limited Announces European Medicines Agency Accepts Alvotech's Marketing Authorization Application for AVT23

European Medicines Agency Approves Alvotech's Proposed Biosimilar to Simponi®? (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech (NasdaqGM:ALVO) acquired Ivers-Lee AG.

Kashiv Biosciences Llc and Advanz Pharma Holdco Limited Announces Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair®? (Omalizumab)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea®? (aflibercept)

Alvotech has completed a Follow-on Equity Offering in the amount of SEK 750 million.

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Alvotech, Annual General Meeting, Jun 25, 2025

Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%

Alvotech has completed a Follow-on Equity Offering in the amount of SEK 38.644416 million.

Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations

Alvotech Provides Revenue Guidance for the Year 2025

Teva Pharmaceuticals and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (Ustekinumab-Aekn) with Stelara®? (Ustekinumab)

Biosimilar Pipeline And R&D Capability Will Open New Markets

Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet

Alvotech Appoints Balaji V. Prasad as Chief Strategy Officer

Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Alvotech to Report Fiscal Year 2024 Results on Mar 26, 2025

Teva Pharmaceuticals and Alvotech Announces the Availability of Selarsdi™? (Ustekinumab-Aekn) Injection in the U.S

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept)

Alvotech and Teva Pharmaceuticals Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, A Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech to Report Q2, 2025 Results on Aug 14, 2025

Alvotech's Position In The Coming Biosimilar Gold Rush

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for Avt05, A Proposed Biosimilar to Simponi (Golimumab)

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva

Alvotech Initiates Confirmatory Patient Study for AVT16

Alvotech: Steady Progress Offers A Good Chance Of Upside

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara